The continuous overhang of geopolitical events is keeping the trends suppressed, as the global cues still have a very deep overhang, leading to market confusion. As the trends ahead show that clarity ...

Opportunities in traditional pharma companies with a focus on domestic formulations and US generic drugs are drying up ...

Most of Wall Street piled into the Magnificent Seven stocks in the past few years, and although a lot of that flow has ...

VYN201 shows promise for vitiligo with once-daily dosing & potential safety benefits, competing with OPZELURA.

Here are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.

ACADIA’s $1B+ 2025 revenue outlook is driven by NUPLAZID and DAYBUE, with ACP-101 offering optional upside despite risks.

The data mining and artificial intelligence (AI) specialist is firing on all cylinders, but the answer is still complicated.

Investors are hopeful a potential trade deal between the U.S. and European Union could bring more certainty to markets ahead ...

UK equities are staging a comeback, but there’s still plenty of value out there, says Rupert Hargreaves UK equities are ...

Small-cap stocks might finally be ready to shine in 2025, thanks to policy shifts and bullish signals. ETFs like IWM, DEEP, ...

Tuya Inc. (NYSE: TUYA) is one of the High Growth Penny Stocks That Are Profitable in 2025. On May 23, Tuya Inc. (NYSE:TUYA) ...